Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in
treating patients with progressive glioblastoma multiforme.